Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlycoVaxyn raises $22 million in series B financing
The round was led by Edmond de Rothschild Investment Partners. Existing investors, Index Ventures and Sofinnova Partners, expressed their commitment to the future of the company through significant
The round was led by Edmond de Rothschild Investment Partners. Existing investors, Index Ventures and Sofinnova Partners, expressed their commitment to the future of the company through significant
The financing will be used to implement a special leasing program in support of Wellstar’s wholly owned subsidiary Trillennium Medical Imaging’s launch of its thermal imaging system. The
Mr Tidmore has served as a member of Orthovita’s board of directors since 2007 and has over 20 years of experience in the spine and orthopedic industry. Mr
According to the company, the LightSheer Duet features two hair removal systems on one versatile platform enabling clinicians to optimize permanent hair reduction anywhere on the body. The
Dr Murphy first joined Lilly in 1980 as a personnel representative in Basingstoke, UK, and was named to his current role in June 2005. During his 28-year career
The marketing authorization application (MAA) submission is based on positive results from a randomized, double-blind, placebo-controlled Phase III study of pazopanib in treatment-naïve and cytokine-pre-treated patients with advanced
Alnylam and Isis were the sole and equal investors in the financing. Regulus was established in September of 2007 by Alnylam and Isis to focus on the discovery,
Aerovance, a biopharmaceutical company, has received clearance from the FDA and the UK Medicines and Healthcare products Regulatory Agency to initiate its Phase IIb clinical trial, AeroTrial, of
This acquisition is reported to be part of Axis-Shield’s strategy to set up direct distribution in key countries such as Germany, which has the potential to become the
Mr Casdagli has been an active investor in life sciences since joining MVM in 2002. Before joining MVM, he worked at PricewaterhouseCoopers where he qualified as a chartered